Search Results - Akira Ooki

  • Showing 1 - 12 results of 12
Refine Results
  1. 1

    Immunotherapy in Colorectal Cancer: Current and Future Strategies by Akira Ooki, Eiji Shinozaki, Kensei Yamaguchi

    Published in Journal of the Anus, Rectum and Colon (2021-01-01)
    Get full text
    Article


  2. 2

    Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma by Akira Ooki, Hiroki Osumi, Keisho Chin, Masayuki Watanabe, Kensei Yamaguchi

    Published in Therapeutic Advances in Medical Oncology (2023-01-01)
    Get full text
    Article


  3. 3

    Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors by Koshiro Fukuda, Hiroki Osumi, Koichiro Yoshino, Izuma Nakayama, Shota Fukuoka, Mariko Ogura, Takeru Wakatsuki, Akira Ooki, Daisuke Takahari, Keisho Chin, Kensei Yamaguchi, Eiji Shinozaki

    Published in BMC Cancer (2023-07-01)
    Get full text
    Article


  4. 4

    Impact of early tumor shrinkage on survival outcomes in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan in third- or later-line settings by Koshiro Fukuda, Hiroki Osumi, Keitaro Shimozaki, Keisho Chin, Mariko Ogura, Shota Fukuoka, Shohei Udagawa, Koichiro Yoshino, Mikako Tamba, Takeru Wakatsuki, Eiji Shinozaki, Kensei Yamaguchi, Akira Ooki

    Published in Therapeutic Advances in Gastroenterology (2025-04-01)
    Get full text
    Article


  5. 5

    Investigating the role of immunotherapy for real-world patients with HER2-negative advanced gastric cancer between 2011 and 2023 by Keitaro Shimozaki, Akira Ooki, Koichiro Yoshino, Mikako Tamba, Shohei Udagawa, Hiroki Osumi, Shota Fukuoka, Izuma Nakayama, Takeru Wakatsuki, Mariko Ogura, Daisuke Takahari, Eiji Shinozaki, Keisho Chin, Kensei Yamaguchi

    Published in Therapeutic Advances in Medical Oncology (2025-02-01)
    Get full text
    Article


  6. 6

    Real-world safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy for locally advanced esophageal squamous cell carcinoma by Mikako Tamba, Hiroki Osumi, Mariko Ogura, Shota Fukuoka, Akihiko Okamura, Jun Kanamori, Yu Imamura, Koichiro Yoshino, Shohei Udagawa, Takeru Wakatsuki, Eiji Shinozaki, Masayuki Watanabe, Kensei Yamaguchi, Keisho Chin, Akira Ooki

    Published in BMC Cancer (2025-04-01)
    Get full text
    Article


  7. 7

    YAP1 induces bladder cancer progression and promotes immune evasion through IL-6/STAT3 pathway and CXCL deregulation by Pritam Sadhukhan, Mingxiao Feng, Emily Illingworth, Ido Sloma, Akira Ooki, Andres Matoso, David Sidransky, Burles A. Johnson III, Luigi Marchionni, Fenna C.M. Sillé, Woonyoung Choi, David McConkey, Mohammad O. Hoque

    Published in The Journal of Clinical Investigation (2025-04-01)
    Get full text
    Article


  8. 8

    Clinical relevance of circulating tumor DNA in HER2-positive advanced gastric cancer: a collaborative study of a phase Ib trial of dual HER2 and PD-1 targeted therapy (Ni-High) by Hiroki Osumi, Takeru Wakatsuki, Akira Ooki, Keisho Chin, Hirokazu Shoji, Mariko Ogura, Izuma Nakayama, Noriko Yamamoto, Hidekazu Hirano, Hiroki Hara, Keiko Minashi, Eiji Shinozaki, Ken Kato, Naoki Ishizuka, Shigehisa Kitano, Kengo Takeuchi, Narikazu Boku, Kensei Yamaguchi, Daisuke Takahari

    Published in Therapeutic Advances in Medical Oncology (2025-09-01)
    Get full text
    Article


  9. 9

    Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II Q... by Akira Ooki, Satoshi Morita, Shigeyoshi Iwamoto, Hiroki Hara, Hiroaki Tanioka, Hironaga Satake, Masato Kataoka, Masahito Kotaka, Yoshinori Kagawa, Masato Nakamura, Tatsushi Shingai, Masashi Ishikawa, Yasuhiro Miyake, Takeshi Suto, Yojiro Hashiguchi, Taichi Yabuno, Junichi Sakamoto, Akihito Tsuji, Masahiko Ando, Kensei Yamaguchi

    Published in Cancer Medicine (2020-03-01)
    Get full text
    Article


  10. 10

    A prospective Phase II study to examine the relationship between quality of life and adverse events of first‐line chemotherapy plus cetuximab in patients with KRAS wild‐type unrese... by Shigeyoshi Iwamoto, Akira Ooki, Satoshi Morita, Hiroki Hara, Hiroaki Tanioka, Hironaga Satake, Masato Kataoka, Masahito Kotaka, Yoshinori Kagawa, Masato Nakamura, Tatsushi Shingai, Masashi Ishikawa, Yasuhiro Miyake, Takeshi Sudo, Yojiro Hashiguchi, Taichi Yabuno, Junichi Sakamoto, Akihito Tsuji, Masahiko Ando, Kensei Yamaguchi

    Published in Cancer Medicine (2018-09-01)
    Get full text
    Article


  11. 11

    Phase 1b/2 study of the liposomal formulation of eribulin (E7389-LF) in combination with nivolumab: Results from the phase 2 esophageal cancer cohort by Takashi Oshima, Sachiko Yamamoto, Hisato Kawakami, Tomoki Makino, Akihito Kawazoe, Toshiki Masuishi, Takahiro Tsushima, Motohiro Hirao, Masahiro Tsuda, Kaori Hino, Noboru Yamamoto, Hiroki Hara, Shota Kaname, Daiko Matsuoka, Yohei Otake, Keisuke Yasuda, Takao Takase, Shuya Takashima, Taro Semba, Akira Ooki

    Published in BJC Reports (2024-09-01)
    Get full text
    Article


  12. 12

    A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer by Hiroki Osumi, Atsuo Takashima, Akira Ooki, Yuri Yoshinari, Takeru Wakatsuki, Hidekazu Hirano, Izuma Nakayama, Natsuko Okita, Ryoichi Sawada, Kota Ouchi, Koshiro Fukuda, Shota Fukuoka, Mariko Ogura, Daisuke Takahari, Keisho Chin, Hirokazu Shoji, Ken Kato, Naoki Ishizuka, Narikazu Boku, Kensei Yamaguchi, Eiji Shinozaki

    Published in Translational Oncology (2023-09-01)
    Get full text
    Article


Search Tools: